U.S. markets close in 1 hour 45 minutes
  • S&P 500

    4,257.46
    +50.19 (+1.19%)
     
  • Dow 30

    33,621.38
    +284.71 (+0.85%)
     
  • Nasdaq

    12,977.73
    +197.82 (+1.55%)
     
  • Russell 2000

    2,006.52
    +31.27 (+1.58%)
     
  • Crude Oil

    92.59
    -1.75 (-1.85%)
     
  • Gold

    1,815.20
    +8.00 (+0.44%)
     
  • Silver

    20.69
    +0.35 (+1.70%)
     
  • EUR/USD

    1.0269
    -0.0056 (-0.54%)
     
  • 10-Yr Bond

    2.8550
    -0.0330 (-1.14%)
     
  • GBP/USD

    1.2146
    -0.0056 (-0.46%)
     
  • USD/JPY

    133.4430
    +0.4440 (+0.33%)
     
  • BTC-USD

    24,000.00
    -280.66 (-1.16%)
     
  • CMC Crypto 200

    570.41
    -0.87 (-0.15%)
     
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • Nikkei 225

    28,546.98
    +727.65 (+2.62%)
     

A number of insiders bought Alimera Sciences, Inc. (NASDAQ:ALIM) stock last year, which is great news for shareholders

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying, like in the case of Alimera Sciences, Inc. (NASDAQ:ALIM), it sends a favourable message to the company's shareholders.

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.

Check out our latest analysis for Alimera Sciences

Alimera Sciences Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider purchase was by President Richard Eiswirth for US$125k worth of shares, at about US$4.45 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$5.50. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

While Alimera Sciences insiders bought shares during the last year, they didn't sell. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

insider-trading-volume
insider-trading-volume

Alimera Sciences is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Does Alimera Sciences Boast High Insider Ownership?

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. Our data suggests Alimera Sciences insiders own 4.1% of the company, worth about US$1.6m. I generally like to see higher levels of ownership.

So What Does This Data Suggest About Alimera Sciences Insiders?

There haven't been any insider transactions in the last three months -- that doesn't mean much. On a brighter note, the transactions over the last year are encouraging. We'd like to see bigger individual holdings. However, we don't see anything to make us think Alimera Sciences insiders are doubting the company. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Case in point: We've spotted 4 warning signs for Alimera Sciences you should be aware of, and 1 of them is significant.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.